The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4^th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.  The event was attended by Fang Zou, the Executive Vice President of the Shanghai Overseas Returned Scholars Association, along with officials from the Liaison Department and cadres from the United Front Work Department of the Pudong New Area District Committee.

At the beginning of the event, the Dutch PhD delegation eagerly visited Medicilon's laboratory, where they closely observed the advanced equipment and innovative technologies in the field of new drug development. They witnessed the efficient operation of state-of-the-art instruments and the meticulous and scientific approach of the research project teams in their daily work. This immersive experience conveyed the vitality and boundless promise inherent in biopharmaceutical technological innovation.

At the symposium, Dr. Chunlin Chen warmly welcomed the Dutch PhD delegation and briefly introduced Medicilon's development history and its achievements in empowerment.  Medicilon has always focused on the field of preclinical research and development. Medicilon has successfully built cutting-edge technology service platforms, including ADC, PROTAC, CGT, small nucleic acids, and antibodies, empowering 480 IND approvals for clinical trials.  Additionally, as a co-founder, the first president, and current honorary president of the Biopharmaceutical Branch of the Shanghai Overseas Returned Scholars Association, as well as a returnee entrepreneur, Dr. Chunlin Chen shared his entrepreneurial insights.  Dr. Chen extended a sincere invitation to the Dutch PhD attendees, expressing his hope that they would work together to promote the high-quality development of the biopharmaceutical industry.

Subsequently, all parties engaged in a lively and in-depth discussion on the future trends of the biopharmaceutical industry, new models of international collaboration, and hot topics in innovation and entrepreneurship.  The participants expressed their commitment to further strengthening communication and collaboration mechanisms, promoting the aggregation and development of various international innovative elements in the Pudong New Area.

The visit of the Dutch PhD delegation to Medicilon not only provided a valuable platform for mutual exchange but also deeply impressed the Dutch scholars with the open, inclusive, collaborative, and innovative entrepreneurial environment in the Pudong New Area.  Looking forward to the near future when these Dutch PhDs return to China after their studies, injecting new vitality into the development of biopharmaceutical entrepreneurship and innovation in Pudong.

Looking ahead, Medicilon will steadfastly uphold the spirit of innovation-driven development and open collaboration. Medicilon will actively broaden its international collaboration horizon, deepen strategic partnerships and technical sharing with top talents and institutions both domestically and internationally. By continuously enhancing its research capabilities, establishing and refining its technology service platforms, Medicilon aims to become a globally trusted comprehensive preclinical research and development service CRO. Medicilon strives to provide robust support for the preclinical development of numerous new and effective drugs.